All In Biotech

NDA 020670 · Medtech Products

Monistat 3 Combination Pack

Miconazole Nitrate · Topical, Vaginal

Last checked: Nov 20, 2026Latest source record: Nov 17, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Apr 16, 1996

Approved uses

1

Original approval plus efficacy supplements

Registered trials

36

8 Phase 3, 0 recruiting

FAERS reports

5,389

994 serious, 91 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 24, 2026.

Uses treats vaginal yeast infections relieves external itching and irritation due to a vaginal yeast infection

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 16, 1996 Original approval · Type 8 - Partial Rx to OTC Switch
1 products under this application
  • MONISTAT 3 COMBINATION PACK · MICONAZOLE NITRATE 2%,200MG · CREAM, SUPPOSITORY, TOPICAL, VAGINAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Miconazole Nitrate" as an intervention, any sponsor and status, largest first.

All 36 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • vulvovaginal burning sensation1,784
  • drug ineffective998
  • vulvovaginal pain945
  • vulvovaginal pruritus572
  • condition aggravated498
  • vulvovaginal discomfort440
  • vaginal haemorrhage415
  • vulvovaginal swelling306
  • pain155
  • hypersensitivity141
  • burning sensation136
  • pruritus132

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200423
200524
200627
200721
200848
200976
201054
201159
201283
201327
201438
201546
2016473
2017428
2018516
2019416
2020461
2021517
2022376
2023290
2024416
2025456
2026514

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 71 on PubMed

Sponsor: Medtech Products

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.